Clinical Trial

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis

Study acronym: DERMIND-AD
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 7 locations 2026-07-29
Trial Details
NCT Number NCT07467564
Lead Sponsor Sanofi
Collaborators: Regeneron Pharmaceuticals
Conditions Atopic Dermatitis
Enrollment 184 participants
Start Date 2026-02-24
Primary Completion 2027-05-24 (estimated)
Study Completion 2027-05-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-28